Literature on the potential spatial heterogeneity of PIK3CA mutations is sparse, but the issue merits further study, not least in light of ongoing trials on the efficacy of 5-ASA treatment in preventing relapse in PIK3CA-mutated CRC (ALASCCA study, NCT02647099). This evidence concerns the gene PIK3CA and colorectal carcinoma.